Is Compounded Semaglutide Still Legal and Safe in 2026?
Compounded semaglutide and tirzepatide are still sold by many telehealth companies, but the rules changed in 2025 when the FDA declared both drug shortages over. Here is what is allowed now, what the FDA has cracked down on, and what to check before you take a compounded GLP-1.
The Short Answer
Compounding semaglutide or tirzepatide is legal only in narrower circumstances than before. While the drugs were on the FDA shortage list, pharmacies could make copies of them. The FDA declared the semaglutide shortage resolved on February 21, 2025, and after transition periods ended (April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities), mass-produced copies are no longer allowed. A licensed pharmacy can still compound a GLP-1 for an individual patient when the prescriber documents a clinical need for a version that differs from the approved product. Tirzepatide went through the same process after its shortage ended.
What Changed When the Shortages Ended
- During a shortage, compounding pharmacies may make copies of an approved drug. That is how compounded semaglutide and tirzepatide became widely available from 2022 onward.
- Once a drug leaves the shortage list, 503A pharmacies may not routinely compound what are essentially copies of it, and 503B outsourcing facilities lose the shortage-based allowance as well.
- Patient-specific compounding remains possible when a prescriber determines that a change (for example a different dose form or the removal of an ingredient the patient can't tolerate) makes a clinically significant difference for that patient.
- This is why many telehealth programs now describe their products as "personalized" or "custom dosed". Whether a given program meets the standard is a question regulators, not marketing, decide.
What the FDA Has Done in 2026
On February 20, 2026, the FDA sent warning letters to 30 telehealth companies selling compounded GLP-1s, made public on March 3. The letters targeted false or misleading marketing: claims that compounded products contain the same ingredients as Wegovy or Zepbound, claims that they had been tested in clinical trials, wording that implied FDA approval, and products sold from outside the US that appeared to be misbranded. The agency warned it could take legal action without further notice.
For consumers, the practical lesson is that marketing language is not evidence. A compounded GLP-1 is not the same product as Wegovy or Zepbound, even when the active ingredient is the same molecule.
The Real Safety Risks
- No FDA review: compounded drugs are not reviewed by the FDA for safety, effectiveness or manufacturing quality before they are sold.
- Dosing errors: in 2024 the FDA reported adverse events, some requiring hospitalization, after patients drew up the wrong amount of compounded semaglutide from multi-dose vials. In most reports patients took five to 20 times the intended dose, often because instructions used "units" instead of milligrams or milliliters. Brand-name products come in pre-filled pens.
- Salt forms: the FDA has warned against compounded products made with semaglutide salts (such as semaglutide sodium or acetate), which are different from the active ingredient in approved drugs.
- Unlicensed sellers: products labeled "for research use only" or sold without a prescription are not legitimate compounded medications.
How to Check a Compounded GLP-1 Provider
- Ask for the name of the pharmacy that fills the prescription, and confirm its license with your state board of pharmacy (or, for an outsourcing facility, the FDA's 503B registration list).
- Make sure a licensed clinician reviews your history and writes a prescription; legitimate providers do not sell GLP-1s without one.
- Ask for the dose in milligrams and the volume in milliliters, plus clear syringe instructions. Don't rely on "units" alone.
- Be wary of claims that the product is "the same as" Wegovy or Zepbound, "FDA-approved" or "clinically proven".
- Read the refund and cancellation terms; compounded medication is made to order and usually can't be returned.
If You'd Rather Use an FDA-Approved Option
Brand-name prices have fallen sharply. In October 2026, Wegovy pills started at $149 a month and Foundayo at $149 a month when bought directly from the manufacturers, the Wegovy pen was $349 at standard doses, and Zepbound was $449 at maintenance doses. With commercial insurance that covers them, savings programs can bring the cost down to as little as $25.